Seeking Alpha

JPMorgan weighs in on the Gilead Sciences (GILD -1.1%)-Pharmasset (VRUS -2.3%) merger after...

JPMorgan weighs in on the Gilead Sciences (GILD -1.1%)-Pharmasset (VRUS -2.3%) merger after Pharmasset amended its phase 2b quantum trails this morning, rocking the boat of hepatitis C-related companies. "This announcement does not trigger a 'key product event' of the merger agreement. As such, we anticipate the deal will close on schedule."
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector